Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)
Animal model studies suggest inhibiting LSD1 could help treat HSV infection. In a mouse model of HSV-1 infection, topical or intraperitoneal treatment with an LSD1 inhibitor decreased viral loads and improved survival compared with vehicle. In a rabbit model of HSV-1 herpetic keratitis in the eye, oral treatment with the LSD1 inhibitor decreased ocular viral loads and disease severity compared with vehicle. In a guinea pig model of genital HSV-2 infection, oral treatment with the LSD1 inhibitor decreased viral shedding and disease severity compared with vehicle. Next steps include evaluating additional LSD1 inhibitors in HSV infection models.
Oryzon Genomics S.A. and Roche have the LSD1 inhibitor ORY-1001 in Phase I/II testing to treat acute myelogenous leukemia (AML). ...